A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome.
dc.contributor.author | Varley, Jennifer | |
dc.contributor.author | McGown, Gail | |
dc.contributor.author | Thorncroft, Mary R | |
dc.contributor.author | Cochrane, S | |
dc.contributor.author | Morrison, P | |
dc.contributor.author | Woll, Penella J | |
dc.contributor.author | Kelsey, Anna M | |
dc.contributor.author | Mitchell, Erika L D | |
dc.contributor.author | Boyle, John M | |
dc.contributor.author | Birch, Jillian M | |
dc.contributor.author | Evans, D Gareth R | |
dc.date.accessioned | 2010-04-01T16:23:20Z | |
dc.date.available | 2010-04-01T16:23:20Z | |
dc.date.issued | 1996-06-06 | |
dc.identifier.citation | A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. 1996, 12 (11):2437-42 Oncogene | en |
dc.identifier.issn | 0950-9232 | |
dc.identifier.pmid | 8649785 | |
dc.identifier.uri | http://hdl.handle.net/10541/95535 | |
dc.description.abstract | We report details of a family with classic Li-Fraumeni syndrome in which there is a mutation in codon 344 of the tumour suppressor gene TP53. Codon 344 is a key residue within the tetramerisation domain, and the amino acid substitution of a proline for a leucine is predicted to have profound implications for tetramerisation and potentially DNA binding. This is the first report of a mutation at this residue in either sporadic tumours or in the germline and the first report of a germline mutation within the tetramerisation domain. The family does not appear to be remarkable in the spectrum of tumours, and there is loss of the wild-type allele in a leiomyosarcoma from the proband. A cell line has been established from the tumour of the proband and cytogenetic and molecular studies carried out, providing an extensive analysis in this family. | |
dc.language.iso | en | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Alleles | |
dc.subject.mesh | Base Sequence | |
dc.subject.mesh | Codon | |
dc.subject.mesh | Female | |
dc.subject.mesh | Genes, p53 | |
dc.subject.mesh | Genotype | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Karyotyping | |
dc.subject.mesh | Li-Fraumeni Syndrome | |
dc.subject.mesh | Male | |
dc.subject.mesh | Molecular Sequence Data | |
dc.subject.mesh | Pedigree | |
dc.subject.mesh | Point Mutation | |
dc.subject.mesh | Sequence Analysis, DNA | |
dc.title | A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. | en |
dc.type | Article | en |
dc.contributor.department | CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Manchester, UK. | en |
dc.identifier.journal | Oncogene | en |
html.description.abstract | We report details of a family with classic Li-Fraumeni syndrome in which there is a mutation in codon 344 of the tumour suppressor gene TP53. Codon 344 is a key residue within the tetramerisation domain, and the amino acid substitution of a proline for a leucine is predicted to have profound implications for tetramerisation and potentially DNA binding. This is the first report of a mutation at this residue in either sporadic tumours or in the germline and the first report of a germline mutation within the tetramerisation domain. The family does not appear to be remarkable in the spectrum of tumours, and there is loss of the wild-type allele in a leiomyosarcoma from the proband. A cell line has been established from the tumour of the proband and cytogenetic and molecular studies carried out, providing an extensive analysis in this family. |